---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-038539"
form_type: "8-K"
ticker: "LBRX"
cik: "0001691082"
company_name: "LB PHARMACEUTICALS INC"
filed_at: "2026-02-05T23:59:59+00:00"
generated_at: "2026-05-16T04:28:43.379852+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LB Pharmaceuticals raises $100M in private placement; Phase 2 MDD trial for LB-102 starts early 2027

## Summary
- Gross proceeds ~$100M from sale of 3.31M shares and 1.42M pre-funded warrants at $21.17/share.
- Investors include Balyasny, Caligan, Commodore, Deep Track, Nantahala, Pivotal, Spruce Street, TCGX, Trails Edge.
- Net proceeds to fund Phase 2 trial of LB-102 as adjunctive MDD treatment and for working capital.
- Phase 2 trial: 380 patients, 50 sites U.S./Europe, randomized 1:1 vs placebo, primary endpoint MADRS-10 at week 6.
- Trial to start early 2027; topline results expected first half 2029.

## SEC filing metadata
- accession: 0001193125-26-038539
- form_type: 8-K
- ticker: LBRX
- cik: 0001691082
- company_name: LB PHARMACEUTICALS INC
- filed_at: 2026-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1691082/000119312526038539/0001193125-26-038539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1691082/000119312526038539/d943290d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-038539
- JSON: https://secwatch.observer/filing/0001193125-26-038539.json
- Plain text: https://secwatch.observer/filing/0001193125-26-038539.txt

## Key facts
- Material Agreements
  LB PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain investors valued at approximately $100.0 million (effective 2026-02-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: approximately $100.0 million
  - Effective: 2026-02-04
  source text: On February 4, 2026, LB Pharmaceuticals Inc (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of (i) 3,306,571 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,417,107 shares of Common Stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1691082/000119312526038539/0001193125-26-038539-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.